Author

E. Papaemmanuil

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 6

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 6 Approach:experimental assay· 4 Assay:whole-genome sequencing· 4 Research Focus:differential expression· 3 Approach:statistical model· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell type annotation· 2 Research Focus:clustering· 2

Frequent Co-Authors

A. J. Mead· 2 shared A. Makohon-Moore· 2 shared A. Rodriguez-Meira· 2 shared C. A. Iacobuzio-Donahue· 2 shared D. Chung· 2 shared D. You· 2 shared F. Maura· 2 shared G. Gundem· 2 shared

Activity by Year

2018-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 26 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. J. Mead

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Chromothripsis orchestrates leukemic transformation in blast phase MPN through targetable amplification of DYRK1A

C. K. Brierley, B. H. Yip, G. Orlando, H. Goyal, S. Wen, J. Wen, M. F. Levine, M. G. Jakobsdottir, A. Rodriguez-Meira, A. Adamo, M. Bashton, A. Hamblin, S. A. Clark, J. O'Sullivan, L. Murphi, , A. J. Mead

The paper identifies chromothripsis-induced amplification of DYRK1A in blast phase MPN as a driver of aggressive disease and a potential therapeutic target.

bioRxiv · Dec 8, 2023 · PreprintCancer Biology

Subclonal somatic copy number alterations emerge and dominate in recurrent osteosarcoma

M. D. Kinnaman, S. Zaccaria, A. Makohon-Moore, B. Arnold, M. Levine, G. Gundem, J. E. A. Ossa, D. Glodzik, M. I. R. Sanchez, N. Bouvier, S. Li, E. Stockfisch, M. Dunigan, C. Cobbs, U. Bhanot, , C. A. Iacobuzio-Donahue

This study identifies subclonal copy number alterations in relapsed osteosarcoma, showing MYC gain/amplification in treatment-resistant clones and their emergence before chemotherapy.

bioRxiv · Jan 5, 2023 · PreprintCancer Biology

Chemotherapy Signatures Map Evolution of Therapy-Related Myeloid Neoplasms

B. T. Diamond, B. Ziccheddu, K. H. Maclachlan, J. Taylor, E. Boyle, J. Arrango Ossa, J. T. Jahn, M. Affer, T. M. Totiger, D. G. Coffey, J. Watts, S. X. Lu, N. Bolli, K. Bolton, J. H. Park, , F. Maura

The paper reconstructs the evolutionary history of therapy-related myeloid neoplasms using chemotherapy-associated mutational signatures and identifies distinct mutational patterns linked to different chemotherapies.

bioRxiv · Apr 26, 2022 · PreprintCancer Biology

Single cell genotyping of matched bone marrow and peripheral blood cells in treatment naive and AZA-treated MDS and CMML

A. Schnegg-Kaufmann, J. A. I. Thoms, G. S. Bhuyan, H. R. Hampton, L. Vaughan, K. Rutherford, P. M. Kakadia, E. M. V. Johansson, T. Failes, G. M. Arndt, J. Koval, R. Lindeman, P. Warbuton, A. Rodriguez-Meira, A. J. Mead, , J. E. Pimanda

This study examines the contribution of mutated hematopoietic stem and progenitor cells to blood cell populations in MDS and CMML before and after AZA treatment.

bioRxiv · Jan 20, 2022 · PreprintCancer Biology

Accelerated single cell seeding in relapsed multiple myeloma

H. J. Landau, V. Yellapantula, B. J. Diamond, E. H. Rustad, K. Maclachlan, G. Gundem, J. Medina-Martinez, J. E. Arango Ossa, M. Levine, Y. Zhou, K. L. Rajya, P. Baez, M. Attiyeh, A. Makohon-Moore, L. Zhang, , F. Maura

This study uses whole genome sequencing to show that relapsed multiple myeloma exhibits accelerated systemic seeding driven by chemotherapy-induced mutations and clonal expansion of single myeloma cells.

bioRxiv · Feb 25, 2020Cancer Biology

Isoform switching as a mechanism of acquired resistance to isocitrate dehydrogenase inhibition

J. J. Harding, M. A. Lowery, A. H. Shih, J. M. Schvartzman, S. Hou, C. Famulare, M. Patel, M. Roshal, R. K. G. Do, A. Zehir, D. You, S. D. Selcuklu, A. Viale, M. S. Tallman, D. M. Hyman, , A. M. Intlekofer

The paper identifies isoform switching between mutant IDH1 and IDH2 as a mechanism of acquired resistance to IDH inhibitors in cancers.

bioRxiv · Aug 1, 2018Cancer Biology